Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 12/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.55 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.54 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1308303 | 0.89 | TP53 (0.78) | GRIK1SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL1308314 | 0.85 | GRIK1 (0.69) | GRIK1SMN1; SMN2HPGDKMT2AKDM4E | |
| SCHEMBL28717905 | 0.84 | NPC1 (0.76) | GRIK1SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL6426650 | 0.83 | KMT2A (0.69) | SMN1; SMN2NPC1HPGDRAB9ATP53 | |
| SCHEMBL3961520 | 0.83 | GRIK1 (1.00) | GRIK1GRIK2 | |
| SCHEMBL1310106 | 0.82 | GRIK1 (0.74) | GRIK1KCNK2KCNK10KMT2AMEN1 | |
| SCHEMBL1308632 | 0.81 | GRIK1 (0.72) | GRIK1RAB9ATP53GRIK2KMT2A | |
| SCHEMBL1308769 | 0.80 | PPARG (0.69) | GRIK1SMN1; SMN2NPC1RAB9AKCNK2 | |
| SCHEMBL1308706 | 0.80 | KCNMA1 (0.74) | GRIK1SMN1; SMN2NPC1HPGDRAB9A | |
| SCHEMBL14856104 | 0.80 | GRIK1 (0.70) | GRIK1SMN1; SMN2NPC1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | GRIK1 2986/4885SMN1; SMN2 3584/4885NPC1 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.